Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

▤ Summary

Genenta Science announced pricing for a registered direct offering that will raise about $15.0 million before fees and expenses. The company will sell 4,285,715 American Depositary Shares at $3.50 per share to institutional investors. Genenta plans to use the net proceeds for working capital and general corporate purposes. The offering is expected to close on or about October 28, 2025, subject to standard closing conditions. Genenta is a clinical-stage immuno-oncology company developing Temferon for solid tumor cancers and other oncology indications.

$ Funding

▦ Linked Companies